Agile Therapeutics Inc. Stock
Agile Therapeutics Inc. Stock
Based on 2 Buy predictions and 2 Sell predictions the sentiment towards Agile Therapeutics Inc. is rather balanced.
With a target price of 11 € there is potential for a 5198.65% increase which would mean more than doubling the current price of 0.21 € for Agile Therapeutics Inc..
Our community identified positive and negative aspects for Agile Therapeutics Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Agile Therapeutics Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Agile Therapeutics Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agile Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Agile Therapeutics Inc. | - | - | - | - | - | - | - |
Ardelyx Inc. | -8.500% | 31.475% | 16.607% | 106.772% | 36.298% | 41.946% | - |
Evolus Inc | -1.640% | 12.150% | -0.826% | 52.866% | 32.597% | 63.265% | - |
Salarius Pharmaceuticals Inc. | -4.230% | -0.971% | -0.971% | -77.826% | -26.486% | -98.326% | -99.993% |
Comments
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
Show more
Ratings data for AGRX provided by MarketBeat